Citotoxicidad diferencial según el régimen de quimioterapia contra las células madre del cáncer de páncreas: estudio preliminar in vitro

Kevin Doello González; Francisco J.Quiñonero; Gloria Perazzoli; Lidia Gago; María Ángeles Chico; Cristina Mesas

doi:10.30827/ars.v63i1.22390

Authors

Kevin Doello González Servicio de Oncología Médica, Hospital Virgen de las Nieves, Granada https://orcid.org/0000-0002-1061-6808
Francisco J.Quiñonero Institute of Biopathology and Regenerative Medicine (IBIMER), Center of Biomedical Research (CIBM), University of Granada, 18100 Granada, Spain. Instituto Biosanitario de Granada (ibs. GRANADA), 18014 Granada, Spain. Department of Anatomy and Embryology, Faculty of Medicine, University of Granada. 18071 Granada, Spain.
Gloria Perazzoli Instituto Biosanitario de Granada (ibs. GRANADA), 18014 Granada, Spain. Department of Anatomy and Embryology, Faculty of Medicine, University of Granada. 18071 Granada, Spain.
Lidia Gago Institute of Biopathology and Regenerative Medicine (IBIMER), Center of Biomedical Research (CIBM), University of Granada, 18100 Granada, Spain. Instituto Biosanitario de Granada (ibs. GRANADA), 18014 Granada, Spain. https://orcid.org/0000-0003-1806-0987
María Ángeles Chico Institute of Biopathology and Regenerative Medicine (IBIMER), Center of Biomedical Research (CIBM), University of Granada, 18100 Granada, Spain. Instituto Biosanitario de Granada (ibs. GRANADA), 18014 Granada, Spain. https://orcid.org/0000-0002-6130-6519
Cristina Mesas Institute of Biopathology and Regenerative Medicine (IBIMER), Center of Biomedical Research (CIBM), University of Granada, 18100 Granada, Spain. Instituto Biosanitario de Granada (ibs. GRANADA), 18014 Granada, Spain. Department of Anatomy and Embryology, Faculty of Medicine, University of Granada. 18071 Granada, Spain. https://orcid.org/0000-0001-6369-5485

DOI:

https://doi.org/10.30827/ars.v63i1.22390

Keywords:

Pancreatic cancer; cancer stem cells; chemoresistance; chemotherapeutic protocols; personalized therapy

Abstract

Introduction: Pancreatic cancer treatment in advanced stages is based on different chemotherapy regimens. Cancer stem cells are responsible for tumor chemoresistance and recurrence in adjuvant and metastatic settings. The objective of this article was to evaluate how these chemotherapeutic regimens affect the proportion of cancer stem cells and the expression of stemness markers.

Method: We used the pancreatic adenocarcinoma cell line PANC-1 as a model to apply different chemotherapeutic protocols (monotherapy and combined therapy) using 5-Fluorouracil, Oxaliplatin, Irinotecan, Gemcitabine and Abraxane.

Results: After analyzing different tumor stem cell markers (SOX2, OCT4, CD133, CD44 and CD24) in pancreatic cancer cells treated with different chemotherapeutic protocols by means of RT-qPCR, Oxaliplatin and Gemcitabine in monotherapy were the chemotherapies that selected the most cancer stem cells while the FOLFIRI protocol decreased them.

Conclusions: Regarding the selection of markers, it has been much higher in the case of Gemcitabine alone. In conclusion, these findings could improve and personalize pancreatic cancer therapy.

Downloads

Download data is not yet available.

References

Kurtanich T, Roos N, Wang G, Yang J, Wang A, Chung EJ. Pancreatic Cancer Gene Therapy Delivered by Nanoparticles. SLAS Technol. 2019;24(2):151-60. doi: 10.1177/2472630318811108.

Thota R, Pauff JM, Berlin JD. Treatment of metastatic pancreatic adenocarcinoma: a review. Oncology (Williston Park). 2014;28(1):70-4.

DeVita VT, Lawrence TS, Rosenberg SA. DeVita, Hellman, and Rosenberg’s cancer: Principles & practice of oncology: Tenth edition. DeVita, Hellman, and Rosenberg’s Cancer: Principles & Practice of Oncology: Tenth Edition. 2015;1-2280.

Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul J-L, et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med. 2018;379(25):2395-406. doi: 10.1056/NEJMoa1809775.

Theocharis AD, Skandalis SS, Gialeli C, Karamanos NK. Extracellular matrix structure. Adv Drug Deliv Rev. 2016;97:4-27. doi: 10.1016/j.addr.2015.11.001.

Quiñonero F, Mesas C, Doello K, Cabeza L, Perazzoli G, Jimenez-Luna C, et al. The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview. Cancer Biol Med. 2019;16(4):688-99. doi: 10.20892/j.issn.2095-3941.2019.0252.

Gzil A, Zarębska I, Bursiewicz W, Antosik P, Grzanka D, Szylberg Ł. Markers of pancreatic cancer stem cells and their clinical and therapeutic implications. Mol Biol Rep. 2019;46(6):6629-45. doi: 10.1007/s11033-019-05058-1.

Herreros-Villanueva M, Bujanda L, Billadeau DD, Zhang J-S. Embryonic stem cell factors and pancreatic cancer. World J Gastroenterol. 2014;20(9):2247-54. doi: 10.3748/wjg.v20.i9.2247.

Yin T, Wei H, Gou S, Shi P, Yang Z, Zhao G, et al. Cancer Stem-Like Cells Enriched in Panc-1 Spheres Possess Increased Migration Ability and Resistance to Gemcitabine. Int J Mol Sci. 2011;12(3):1595-604. doi: 10.3390/ijms12031595.

Hz Y, Y M, Y Z, Lm X, Xj C, Wb D, et al. Autophagy contributes to the enrichment and survival of colorectal cancer stem cells under oxaliplatin treatment. Cancer Lett. 2015;361(1):128-36. doi: 10.1080/15548627.2017.1290751.

Su P, Yang Y, Wang G, Chen X, Ju Y. Curcumin attenuates resistance to irinotecan via induction of apoptosis of cancer stem cells in chemoresistant colon cancer cells. Int J Oncol. 2018;53(3):1343-53. doi: 10.3892/ijo.2018.4461.

Craveiro V, Yang-Hartwich Y, Holmberg JC, Joo WD, Sumi NJ, Pizzonia J, et al. Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment. Cancer Med. 2013;2(6):751-62. doi: 10.1002/cam4.115.

Xu Z-Y, Tang J-N, Xie H-X, Du Y-A, Huang L, Yu P-F, et al. 5-Fluorouracil Chemotherapy of Gastric Cancer Generates Residual Cells with Properties of Cancer Stem Cells. Int J Biol Sci. 2015;11(3):284-94. doi: 10.7150/ijbs.10248.